11th Apr 2016 11:18
LONDON (Alliance News) - GW Pharmaceuticals PLC said Monday it has begun a phase III clinical trial of Epidiolex for the treatment of seizures related to Tuberous Sclerosis Complex, a rare genetic disorder, the most common symptom of which is epilepsy.
This is the third indication GW Pharmaceuticals is targeting with Epidiolex, along with late stage trials in childhood epilepsies Dravet syndrome and Lennox-Gastaut syndrome.
"We are pleased to announce the start of this pivotal clinical trial of Epidiolex in TSC, which follows the recent positive results from our trial in patients with Dravet syndrome. Our decision to evaluate Epidiolex in TSC is based on findings from the physician-led Epidiolex expanded access program, which found that TSC patients reported reductions in seizure activity," said Chief Executive Officer Justin Gover in a statement.
Shares in GW Pharmaceuticals were down 0.3% at 466.00 pence Monday afternoon.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
GWP.L